<table><tr><th>From:</th><th>Richard Kahn</th></tr><tr><td>Sent:</td><td>Thursday, August 13, 2015 9:03 PM</td></tr><tr><td>To:</td><td>jeffrey E.</td></tr><tr><td>Subject:</td><td>Avalanche Biotechnologies beats by $0.01, misses on revenue</td></tr></table>

Aug 13 2015, 16:45 ET | About: Avalanche Biotechnologies (AAVL) <http://seekingalpha.com/symbol/AAVL> | By: Mohit Manghnani <http://seekingalpha.com/author/sa-editor-mohit-manghnani>, SA News Editor <http://seekingalpha.com/images/mail_icon.png>

•

- Avalanche Biotechnologies (NASDAQ:AAVL <http://seekingalpha.com/symbol/aavl> ): Q2 EPS of -$0.38 beats by $0.01.

* Revenue of $0.2M (+42.9% Y/Y) misses by $0.56M.

	- Shares -13.2%.

http://seekingalpha.com/pr/14409436-avalanche-biotechnologies-inc-reports-second-quarter-2015-financial-results-and-provides-update-on-avaminus-101-program

Richard Kahn
HBRK Associates Inc.
575 Lexington Avenue 4th Floor
New York, NY 10022
tel 212-971-1306
fax 646-350-0954
cell 917-414-7584